FDA Expands Use of Botox and Dysport for Pediatric Spasticity
The FDA has approved the expanded use of Botox® for the treatment of spasticity in pediatric patients aged ≥2 years, including those with lower limb spasticity caused by cerebral palsy.
The FDA has approved the expanded use of Botox® for the treatment of spasticity in pediatric patients aged ≥2 years, including those with lower limb spasticity caused by cerebral palsy.
The odds of knee osteoarthritis are increased in association with heavy physically demanding occupations and occupational activities.
Evidence suggests that the prevalence of chronic opioid use among patients with RA has increased over the last decade.
The FDA has accepted for review the Biologics License Application (BLA) for tanezumab 2.5mg administered subcutaneously for moderate to severe OA pain.
The researchers found that 13.1% of patients with musculoskeletal conditions were opioid users, and those using prescribed opioids were more likely to be highly satisfied with their care.
Trigger point injection as an adjunct to physical therapy is well tolerated and improves symptoms of pelvic floor muscle spasm in approximately 50% of patients with chronic prostatitis/chronic pelvic pain syndrome.
Muscle MRI may complement a physician’s objective assessment in juvenile dermatomyositis, although negative MRI findings should not preclude treatment continuation.
A relationship may be present between serum vitamin D levels and chronic tension-type headaches.
Outcome measurement tools for psoriatic arthritis have been updated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis.